Case-based review demonstrates canakinumab's effectiveness in treating Schnitzler syndrome when anakinra fails, indicating a promising alternative therapy.
Schnitzler syndrome is a rare autoinflammatory syndrome caused by a dysregulation of the interleukin‐1β signalling pathway. Symptoms tend to appear in middle age and include urticariform skin lesions, fever, bone pain, lymphadenopathy and IgM monoclonal gammopathy. Interleukin‐1 (IL‐1) targeted therapy constitutes the basis for treatment and can lead to complete resolution of symptoms. We report a case of Schnitzler syndrome in a 49‐year‐old man refractory to anakinra and subsequently treated successfully with canakinumab.
No takes yet. Share an insight, caveat, or question.
Belinchón et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: